Oculis CHF 20m Financing Round

Oculis, a clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, announced the completion of a CHF 20m Series B financing. The round involved a syndicate of leading transatlantic life sciences investors composed of Novartis Venture Fund, Pivotal bioVenture Partners and Bay City Capital as well as existing investors including Brunnur Ventures and Silfurberg.

In connection with this financing, Oculis is relocating its corporate headquarters to Lausanne, Switzerland, while keeping its R&D activities in Reykjavik, Iceland.

VISCHER acted as counsel to the new investors with respect to the financing and assisted Oculis with its relocation to Switzerland. The team was led by Dr. Matthias Staehelin (Partner, Corporate) and Nadia Tarolli (Partner, Tax) with the support of Vincent S. Reardon (Senior Associate, Corporate), Luzius Zumstein (Associate, Corporate) and Adrian Briner (Associate, Tax).



Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.

Learn more …

News Alerts

Here you will find the frequent news alerts in the fields tax, litigation and arbitration, public sector and regulatory, corporate and commercial law and intellectual property law.

Learn more

Subscribe to news alert


Schützengasse 1, Postfach 5090, 8021 Zürich
Phone +41 58 211 34 00, Fax +41 58 211 34 10

Aeschenvorstadt 4, Postfach 526, 4010 Basel
Phone +41 58 211 33 00, Fax +41 58 211 33 10

Map and Directions